Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for this interesting post ATL.
It would be something if the CI (with still very nasty side effects) could be replaced by vitamin C.
GLTU
alphapuppy,
I think it is about the safe reduction of tumor size over time.
So far it seems that only DCvax and chemo/rad can really get to the tumor and damage the antigens and even eliminate them.
The big difference is that DCvax does this completely without any harmful side effects while chemo/rad is a horror for the entire body.
So giving DCvax and then watching the reduction, over time, of tumor size can be a blessing in disguise.
GLTU
"But we would now like to do some more focused, faster path, tumor shrinkage endpoint trials. So we are, as we evaluate, I mean, we have so many opportunities in front of us now. Really, the challenge is choosing. Right? And so we we gotta steer ourselves, to the extent we can, towards that direction, to more shrinkage endpoints".
And combining these tumor response trials with the tumor agnostic, offers far-reaching possibilities.
Right?
GLTU
Here’s a brief summary.
1. DCVax activates T cells to fight the cancer tumor. It is very effective but the effect is mitigated somewhat by a tumor defense. The tumor sends out PD-L1 proteins to attach to the T cell’s PD-1 receptor. When activated, this is a checkpoint that down-regulates the T cell.
2. So, a PD-1 inhibitor, aka checkpoint inhibitor (CI), neo-adjuvant drug was added. It is very effective in fighting this tumor’s defense.
(Thanks to Chiugray).
No trading in NWBO ??
Thank you lykiri.
GLTU
🇩🇰 The Danish Dude 🇩🇰
@FlemmingBruce
$NWBO
She not only was a finalist, she WON New York Law Journal’s Attorney of the Year Award for 2024.
And under a year ago, she was appointed president of the Institute for Law and Economic Policy.
Watch her gobble up 7 market makers RAW!
https://twitter.com/FlemmingBruce/status/1833439231621931285/photo/1
" That would look like a different company indeed ".
Exactly what LP said in the last ASM.
GLTU
The network here in Holland is also getting bigger and bigger.
In the past few days minions were added and 200 k were bought.
In total now many more people than a few months before.
GLTU
"And yet, any (potential) lock up would need to be published, for regulatory reasons. So as far as I’m concerned, NWBO is foot loose and fancy free to consider offers from any larger bidders. What if Eli or Novo make any (potential) bid public"?
Then all hell breaks loose I think!
Wonderful.
GLTU
Thanks laser,
The only thing NWBO does NOT own is the land, the building and the employees. The land and the building is, we can safely say, contrary to what the nay sayers say, that the vast majority of Advent's turnover goes to NWBO and of course the large profit margin as well.
Too bad for the short family.
" At September 30, 2019, the Company had operating lease liabilities of approximately $4.9 million for both the 20-year lease of the building for the manufacturing facility in Sawston, U.K., and the current office lease in the U.S. and ROU of approximately $4.5 million for the Sawston lease and US office lease, which were included in the condensed consolidated balance sheet " .
https://www.sec.gov/Archives/edgar/data/1072379/000110465919062726/tm1919565d1_10q.htm
GLTAL
I wrote : a total of $ 60 B.
GLTU
I think Advent alone is worth $20B considering what has been paid on the market for a major, well-functioning CDMO.
With that a very high P/E, considering the enormous growth potential I would say 40.
Revenues cannot be estimated but with approximately (wild guess) 5000 patients per year for Glio 3/4 alone to start in the UK, for let's say $150,000 pp, that is let's say 1B.
Then I come to an estimate of a total of $60B in the not too distant future.
GLTU
Henry
@HenryMuney
$NWBO Patent granted on September 2, 2024 - 🇮🇱 IL256522 - "Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response"
https://patentscope.wipo.int/search/en/detail.jsf?docId=IL214953959
10:42 PM · Sep 3, 2024
·
1,780
Views
Thank you Captain for your good work!
GLTU
And ofcourse we have this one Doc logic:
" Apparently, according to this article that was published last week on 1/15/2024, researchers at UCLA, including Dr. Linda Liau, Dr. Timothy Cloughesy and Dr. Phionah NghiemPhu, have been able to use CRISPR gene editing technology to change unmethylated GBM patients into methylated GBM patients".
ATL: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173680608
GLTU.
Peter Davis
@peter_brit
#dcvax $nwbo #gbm
Tumour-agnostic oncology – time has come to re-think clinical research
27 Aug 2024
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
📷
The traditional characterisation of the disease by the organ in which it originated continues to determine how cancer care is delivered: for patients, having breast, lung or colon cancer defines which hospital department and doctor they will be referred to and, in the majority of cases, which treatments and clinical trials they will have access to. A comment in Nature recently illustrated how the organ-based classification of cancers and sequential testing of new medicines in defined tumour types has delayed patients’ access to innovative treatments—in some cases by several years. “We urgently need a new approach to classifying oncological diseases, to bring clinical research in line with modern oncology, cutting down costs and resources,” says Prof Fabrice André, Director of Research at Gustave Roussy Cancer Campus in France, co-author of the above-mentioned article and ESMO President-Elect.
Tissue-agnostic research is an emerging field founded on the observation that sometimes the molecular determinants of response to a medicine can be shared between cancers. Conducting tumour-agnostic trials holds the promise of expediting clinical research while containing costs. “However, the implementation of this type of approach has so far been limited by the lack of a standard methodology for pharmaceutical companies to design their registration trials and for regulators to be able to issue tumour-agnostic approvals,” explains André. “Crucial questions include, for example, how many patients should be enrolled for each tumour site, how to define the relevant biomarker, and how to test whether some cancers should be excluded from the approval.”
ESMO is working actively in this area, and the release of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) for assessing the tumour-agnostic potential of molecularly guided therapies could contribute to a common understanding among regulators and the clinical research community of the conditions in which tissue-agnostic development should be preferred to conventional trials. (Ann Oncol. 2024; Articles in press) Going forward, more research will also be necessary to develop standard criteria for defining when a biomarker can be considered as tumour-agnostic in the first place.
Preparing the wider ecosystem to support the change
The body of knowledge available on the genomic landscape at DNA level across cancers, André argues, is now mature enough to support such a shift. Rapid scientific and therapeutic advances are also what prompted ESMO to update its recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer earlier this year (Ann Oncol. 2024; Articles in press). Among other developments, testing recommendations have been extended to various new tumour types including rare cancers, covering both ESCAT tier I alterations and tier II investigational biomarkers, as well as selected tumour-agnostic biomarkers where patients have access to matched therapies.
But is the oncology community ready to become tumour-agnostic? “Patients themselves are increasingly demanding rapid access to targeted therapies. The question of the field’s maturity for tissue-agnostic research is not about whether people are going to agree or not, but rather ‘what is the benefit for the patient?’,” André highlights.
Cancer care evolution towards a tumour-agnostic approach comes with the need for a change in education for medical oncologists. For André, the era when clinicians simply needed to know how to interpret a clinical trial is over. “Today oncologists also need a strong background in biology and a deep understanding of the molecular and cellular mechanisms of disease—knowledge that is indispensable for them to integrate and implement information they receive both in genomic reports and in reporting of future biomarker-driven, tissue-agnostic trials,” he says. ESMO has a key role to play in producing and disseminating advanced learning resources and continuing education in the so-called molecular oncology, and André believes that also patients should be part of this process.
“Importantly, patients need to be educated in this new era of cancer care and learn to perceive their cancer by its molecular mechanism rather than by the location of the tumour. This may help them understand why they are receiving one treatment rather than another, and feel more engaged in clinical research,” he concludes.
Griffin and his brothers in crime with their spoofing manipulations ( and therby naked shorting) are the reason for the shareprice.
And not the management with all the milestones achieved and dodging the Wall Street Mafia TO BANKRUPT THEM and not the dilution. .
We will have the 100% proof out soon.
Congrats ATL,
I'm sure it all will work out !
Best to you.
ilovetech,
I am of course very curious about the outcome of the Trial with Keytruda ,Poli-ICLC and DCvax !
But another 2 failures for Merck now could perhaps mean that they have finally thrown in the towel regarding their own Trials and that they finally realize that they cannot achieve anything without NWBO.
Then we finally have a BP on our side.
Best to you.
Peter Davis
@peter_brit
·
2h
#dcvax $nwbo #gbm
Two more Keytruda Phase 3 failures from Merck..
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
https://merck.com/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials/
August 29, 2024
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and
Show more
$NWBO Just looking over the Cohen Representation for NWBIO, I still find it interesting Raymond Sarola was added to the team well into the case. Keep wondering if a whistle blower may have stepped forward?
— SemperFITrader (@SouthernDrive21) August 25, 2024
"Ray also represents clients in whistleblower matters" pic.twitter.com/uHaEhVshFq
Post
See new posts
Conversation
maverick_1 reposted
SemperFITrader
@SouthernDrive21
$NWBO Just looking over the Cohen Representation for NWBIO, I still find it interesting Raymond Sarola was added to the team well into the case. Keep wondering if a whistle blower may have stepped forward?
"Ray also represents clients in whistleblower matters"
Thanks for your pm, Steady_T.
I can't respond with pm.
GLTU
No problem DJPele.
Best to you
For one person the opinion is realistic, for another the same opinion is a joke.
Based on achieved milestones and comparisons with acquired companies for several billions that are not even worth 10% of what NWBO has achieved so far.
And of course also much less efficient, as has now been proven.
Are you starting now too?
No, in Holland.
I'm a Dutchman.
Thanks for your response antihama.
I honestly had no idea and thought DJPele was serious.
Learned something again :)
GLTU
DJPele,
Can you tell me who or what Lowe is?
Thanks in advance for an answer.
GLTU
Thank you.
brooktrail,
If this is really the case, it is virtually a crime to prolong the process for another year.
Patients are waiting.
GLTU
Thanks dstock.
A lot of ambiguity.
GLTU